Pre-Launch Medical Affairs and RWE Strategy for Rare Disease Therapy
-
Small biotech needed to build a compelling evidence narrative to support payer formulary positioning and HCP
uptake ahead of launch.
- Required a clearer view of disease burden and patient need in a rare disease population.
- Also needed targeted KOL engagement to inform medical affairs strategy and market readiness.
- Used RWE claims data to assess burden of disease and sharpen the patient narrative.
- Built RWE evidence inputs for the PIE deck and broader medical affairs story.
- Conducted KOL targeting to prioritize key stakeholders and strengthen pre-launch engagement strategy.
- Positioned the evidence narrative to support both payer value communication and HCP education.
- Strengthened pre-launch evidence narrative around disease burden, unmet need, and product value.
- Supported more targeted medical affairs and stakeholder engagement planning.
- Laid the foundation for payer access discussions and early HCP uptake.
